hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06336876, orgStudyIdInfo id: 080.EDU.2019.R, briefTitle: Perceived Coping, Meaning, and Joy at Work, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-06-30, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Methodist Health System, class: OTHER, descriptionModule briefSummary: The aim of this study is to assess and describe employee characteristics associated with perceived horizontal inter-collegial workplace uncivil behavior within nursing services, and identify any relationships with meaning and joy in work (MJW), and assess job satisfaction., conditionsModule conditions: Undefined, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Survey, outcomesModule primaryOutcomes measure: Workplace Incivil Behavior, primaryOutcomes measure: Meaning, Joy in Work, primaryOutcomes measure: Occupational Coping Self-Efficacy, primaryOutcomes measure: Demographic, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Methodist Richardson Medical Center, status: RECRUITING, city: Richardson, state: Texas, zip: 75082, country: United States, contacts name: Maxine Adegbola, RN, role: CONTACT, phone: 214-876-9767, email: maxineadegbola@mhd.com, contacts name: Maxine Adegbola, RN, role: PRINCIPAL_INVESTIGATOR, contacts name: David Irvan, RN, role: SUB_INVESTIGATOR, contacts name: Terri Daugherty, RN, role: SUB_INVESTIGATOR, contacts name: Joanna Bender, RN, role: SUB_INVESTIGATOR, contacts name: Tabitha Moore, RN, role: SUB_INVESTIGATOR, contacts name: Sharon Blackerby, RN, role: SUB_INVESTIGATOR, contacts name: Katherine Hartdegen, RN, role: SUB_INVESTIGATOR, contacts name: Melissa Miller, RN, role: SUB_INVESTIGATOR, contacts name: Shannon Jackson, RN, role: SUB_INVESTIGATOR, contacts name: Obed Thomas, RN, role: SUB_INVESTIGATOR, geoPoint lat: 32.94818, lon: -96.72972, hasResults: False
protocolSection identificationModule nctId: NCT06336863, orgStudyIdInfo id: STU-2023-1151, briefTitle: Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: University of Texas Southwestern Medical Center, class: OTHER, descriptionModule briefSummary: The purpose of the study is to provide immunosuppression weaning and/or monitoring for an additional 12-months to evaluate the safety and efficacy of belatacept monotherapy in patients previously enrolled in the clinical trial: "Use of donor derived-cell free DNA (AlloSure) and gene expression profiling (AlloMap Kidney) to facilitate Belatacept monotherapy in kidney transplant patients.", conditionsModule conditions: Kidney Transplant Immunosuppression, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Allosure and TruGraf, interventions name: Immunosuppression Taper, outcomesModule primaryOutcomes measure: Incidence of acute kidney graft rejection, primaryOutcomes measure: Incidence of facilitation to Belatacept monotherapy, secondaryOutcomes measure: Patient Survival after Immunosuppression Wean, secondaryOutcomes measure: Kidney Graft Failure after Immunosuppression Wean, secondaryOutcomes measure: Mean change in Estimated Glomerular Filtration Rate (eGFR) after Immunosuppression Wean, secondaryOutcomes measure: Incidence of Proteinuria after Immunosuppression Wean, secondaryOutcomes measure: Incidence of de-novo donor specific antibodies (dnDSA), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Texas Southwestern Medical Center, city: Dallas, state: Texas, zip: 75390, country: United States, contacts name: David Wojciechowski, DO, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.78306, lon: -96.80667, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2024-03-06, uploadDate: 2024-03-28T09:25, filename: Prot_SAP_000.pdf, size: 293395, hasResults: False
protocolSection identificationModule nctId: NCT06336850, orgStudyIdInfo id: 069.GID.2020.D, briefTitle: Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-12-23, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Methodist Health System, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy, safety, and adequacy of Endoscopic Ultrasound (EUS) Portal Pressure Gradient Measurement (PPGM) in patients undergoing EUS-guided liver biopsies., conditionsModule conditions: Liver Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement, outcomesModule primaryOutcomes measure: Portal Pressure Gradient Measurements from Hepatic and Portal Veins, secondaryOutcomes measure: Correlation between Portal Pressure Gradient Measurements and the presence or absence of portal hypertension, secondaryOutcomes measure: Clinical significance between portal pressure gradient measurement and portal hypertension, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Methodist Dallas Medical Center, status: RECRUITING, city: Dallas, state: Texas, zip: 75203, country: United States, contacts name: Prashant Kedia, MD, role: CONTACT, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False
protocolSection identificationModule nctId: NCT06336837, orgStudyIdInfo id: 24-3T/48, briefTitle: False Positive Peripheral Blood Culture in Children With Leukaemia: A Prevalence Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Ege University, class: OTHER, descriptionModule briefSummary: Chemotherapy, the main treatment for childhood leukemia, has side effects on healthy cells. One of the most important of these side effects is the risk of infection due to neutropenia. In clinics, blood culture is the gold standard for the detection of possible infection risk (bacteremia, fungemia, etc.). During the diagnosis and treatment process in children with leukemia, a large number of peripheral or catheter blood cultures are performed. When the culture results are positive, it is accepted that the infection has grown. In some cases, a positive peripheral blood culture result may not be clinically significant. An agent belonging to the skin flora of the patient or the healthcare professional taking the field culture may also cause the blood culture result to be positive. This is called contamination or false positive blood culture. Contaminated cultures may cause prolonged hospitalization, additional medical interventions, unnecessary initiation of antibiotic treatment and related antibiotic resistance, toxicity due to additional drugs and an increase in hospital costs. The peripheral blood culture contamination rate, which is accepted as a quality indicator in some countries, should be below 3%.In this context, this study aimed to determine the prevalence of false positive peripheral blood cultures by examining the peripheral blood culture results obtained during routine follow-ups from children hospitalized with leukemia in the pediatric hematology clinic. The data will be collected retrospectively covering three years before March 2024 when the ethics committee approval was obtained. Since the relevant clinic cares for approximately 25 new children diagnosed with leukemia annually, the study sample is planned as 75 cases., conditionsModule conditions: Nurse's Role, conditions: Leukemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: blood culture contamination rate, eligibilityModule sex: ALL, minimumAge: 0 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ege University, status: RECRUITING, city: İzmir, zip: 35100, country: Turkey, contacts name: Seda ARDAHAN SEVGILI, PhD, role: CONTACT, phone: 00905544318390, email: sedardahan@gmail.com, contacts name: Figen YARDIMCI, PhD, role: CONTACT, email: figenyardimci@gmail.com, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06336811, orgStudyIdInfo id: DEU active-pasive VR, briefTitle: Virtual Reality Distraction During Phlebotomy in Children, acronym: activeVR, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-30, primaryCompletionDateStruct date: 2023-12-30, completionDateStruct date: 2023-12-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Dokuz Eylul University, class: OTHER, descriptionModule briefSummary: This randomized controlled study was conducted to evaluate the effect of distraction methods using virtual reality on the emotional appearance, pain, fear, and anxiety associated with the procedure during phlebotomy in children aged 6-12 in a private blood collection unit., conditionsModule conditions: Pain, Acute, conditions: Child, Only, conditions: Anxiety and Fear, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Before blood collection, the "Emotional Appreance Scale for Children" was evaluated by a non-researcher nurse. Pediatric patients between the ages of 6 and 12, from whom blood would be collected, were distributed to groups according to the randomization scheme., whoMasked: INVESTIGATOR, enrollmentInfo count: 150, type: ACTUAL, armsInterventionsModule interventions name: passive virtual reality distraction, interventions name: active virtual reality distraction, outcomesModule primaryOutcomes measure: procedure related pain, primaryOutcomes measure: anxiety, primaryOutcomes measure: fear, primaryOutcomes measure: emotional apperance, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Gülçin Özalp Gerçeker, city: İzmir, zip: 35100, country: Turkey, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06336798, orgStudyIdInfo id: STUDY00005871, secondaryIdInfos id: K23HL166775, type: NIH, link: https://reporter.nih.gov/quickSearch/K23HL166775, briefTitle: Bioenergetic Effect of Pioglitazone in CLD-PH, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-08, completionDateStruct date: 2028-08, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Emory University, class: OTHER, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), descriptionModule briefSummary: The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is:• Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD.Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo)., conditionsModule conditions: Pulmonary Hypertension, conditions: Pulmonary Hypertension Due to Lung Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Pioglitazone 30mg, interventions name: Placebo, interventions name: Labs, outcomesModule primaryOutcomes measure: Change in Mitochondrial metabolism parameters: Spare respiratory capacity, primaryOutcomes measure: Change in Mitochondrial metabolism parameters: Maximal respiration, primaryOutcomes measure: Change in Mitochondrial metabolism parameters: Basal respiration, secondaryOutcomes measure: Number of hypoglycemia incidences, secondaryOutcomes measure: Number of participants with leg edema, secondaryOutcomes measure: Change in BNP levels, secondaryOutcomes measure: Change in Six minute walk distance (6MWT), secondaryOutcomes measure: Change in Borg dyspnea score, secondaryOutcomes measure: Change in NYHA/WHO Functional Classification, secondaryOutcomes measure: Change in University of California San Diego Shortness of Breath Questionnaire score, secondaryOutcomes measure: Change in emPHasis-10 Questionnaire score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336785, orgStudyIdInfo id: 04-2023-HIT-K&S, briefTitle: Kiss and Smile HIT, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-02, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Erevna Innovations Inc., class: OTHER, descriptionModule briefSummary: The "Holistic Individualized Treatment" (HIT) approach is used to identify treatment priorities, focus areas, and appropriate products for soft tissue filler treatments.The "Kiss and Smile HIT" considers lip volume, lip framing and expression to improve patients appearance. This trial will assess the effectiveness of the Kiss and Smile HIT algorithm in treating patients with different kiss and smile related issues (e.g. volume loss, lips lack proper framing, lack of a confident smile due to issues with expression)., conditionsModule conditions: Aesthetic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Restylane line of dermal fillers and Dysport neuromodulator, outcomesModule primaryOutcomes measure: Global Aesthetic Improvement Scale (GAIS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erevna Innovations Inc., status: RECRUITING, city: Montréal, state: Quebec, zip: H3R3A1, country: Canada, contacts name: Andreas Nikolis, MD, role: CONTACT, phone: 514-488-0163, email: research@vicpark.com, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06336772, orgStudyIdInfo id: 10-2023-GAL-SHYP, briefTitle: Restylane Shaype Versus Juvederm Volux for Chin Augmentation, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-10-23, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-11-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Erevna Innovations Inc., class: OTHER, descriptionModule briefSummary: This study aims to compare two injectable products (Restylane Shaype and Juvéderm Volux) for aesthetic augmentation of the chin, conditionsModule conditions: Chin Retrusion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Restylane Shaype, interventions name: Juvéderm Volux, outcomesModule primaryOutcomes measure: Statistically significant group differences in the average three-dimensional volumetric increase since baseline, secondaryOutcomes measure: Treatment group differences assessed by blinded evaluations on a validated chin retrusion scale (Galderma Chin Retrusion Scale), secondaryOutcomes measure: Treatment group differences assessed by blinded evaluations of aesthetic improvement (Global Aesthetic Improvement Scale), secondaryOutcomes measure: Assessment of product integration by means of ultrasound (the radius or surface area of in vivo product placed within tissues, integration [or lack thereof] of the product into the surrounding tissues), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erevna Innovations Inc., city: Montréal, state: Quebec, zip: H3R3A1, country: Canada, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06336759, orgStudyIdInfo id: 2021-10-GAL-JWL, briefTitle: Safety and Efficacy of Fillers for Contouring the Jawline, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-11-11, primaryCompletionDateStruct date: 2022-12-14, completionDateStruct date: 2023-11-10, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Erevna Innovations Inc., class: OTHER, descriptionModule briefSummary: The study aims to evaluate the safety and efficacy of two hyaluronic acid products, Restylane Lyft and Defyne, for contouring the jawline and chin, addressing concerns about contour deficits in patients seeking aesthetic treatments., conditionsModule conditions: Jawline Contour Deficit, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Restylane Defyne, interventions name: Restylane Lyft, outcomesModule primaryOutcomes measure: Frequency of subjects having at least "improved" since Baseline, as per the Global Aesthetic Improvement Scale (GAIS), primaryOutcomes measure: Frequency of subjects displaying at least a one grade improvement since Baseline, on the Raspaldo (2008) Jawline Scale, secondaryOutcomes measure: Frequency of subjects having at least "improved" since Baseline, as per the Global Aesthetic Improvement Scale (GAIS), secondaryOutcomes measure: Frequency of subjects displaying at least a one grade improvement since Baseline, on the Raspaldo Jawline Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erevna Innovations Inc., city: Montréal, state: Quebec, zip: H3R3A1, country: Canada, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06336746, orgStudyIdInfo id: RHenningsson, briefTitle: Effects of Steep Trendelenburg and Pneumoperitoneum on Cardiac Performance., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Karlstad Central Hospital, class: OTHER, descriptionModule briefSummary: The field of robotic-assisted laparoscopic surgery increases all the time. Older and more fragile patients which are not suitable for major open surgery could be scheduled for robotic- assisted surgery. The peroperative anesthesiological challenges and stresses during this type of surgery could anyway be even more prominent.The extreme positioning of patients during robotic surgery in the pelvis, often 30 degrees head down tilting (Trendelenburg positioning), should increase the work load of the heart significantly. There are no studies concerning fragile patients with heart failure during these conditions.In this study the circulatory effects in patients with normal heart function and preexisting heart failure will be studied during robotic surgery in extreme Trendelenburg positioningDuring surgery the work load and performance of the heart will be monitored using an esophageal doppler and optical spectrophotometry measuring regional saturation of the brain. This study can identify patients at risk of developing critical circulatory failure during this type of surgery., conditionsModule conditions: Heart Failure, Systolic, conditions: Robotic Surgery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Esophageal Doppler, outcomesModule primaryOutcomes measure: Change of Stroke Volume during Trendelenburg position and pneumoperitoneum., secondaryOutcomes measure: % Change of Systemic Vascular Resistance;PulsePressureVariation; Peak Velocity; Stroke Volume Variation and FlowTimeCorrected, secondaryOutcomes measure: % change in regional brain saturation rSO2 during Trendelenburg position and pneumooperitoneum., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dpt of Anesthesiology&Intensive Care; Central Hospital of Karlstad, city: Karlstad, state: Värmland, zip: 65230, country: Sweden, contacts name: Ragnar N Henningsson, Associate Professor, role: CONTACT, phone: +461083317434, email: ragnar.henningsson@regionvarmland.se, geoPoint lat: 59.3793, lon: 13.50357, hasResults: False